Results 21 to 30 of about 37,266 (235)

Classification of Heart Failure According to Ejection Fraction JACC Review Topic of the Week [PDF]

, 2021
The recent U.S. Food and Drug Administration expanded indication for sacubitril/valsartan introduces a new potential taxonomy for heart failure, with no reference to "preserved" ejection fraction but referring to "below normal" ejection fraction as those
Lam, Carolyn S. P., Solomon, Scott D.
core   +1 more source

Sirt1 Activity in PBMCs as a Biomarker of Different Heart Failure Phenotypes

Biomolecules, 2020
Heart Failure (HF) is a syndrome, which implies the existence of different phenotypes. The new categorization includes patients with preserved ejection fraction (HFpEF), mid-range EF (HFmrEF), and reduced EF (HFrEF) but the molecular mechanisms involved ...
Valeria Conti, Graziamaria Corbi, Maria Vincenza Polito, Michele Ciccarelli, Valentina Manzo, Martina Torsiello, Emanuela De Bellis, Federica D’Auria, Gennaro Vitulano, Federico Piscione, Albino Carrizzo, Paola Di Pietro, Carmine Vecchione, Nicola Ferrara, Amelia Filippelli   +14 more
doaj   +1 more source

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial

ESC Heart Failure, 2022
Aims In the heart failure (HF) with preserved ejection fraction (HFpEF) PARAGON‐HF trial, sacubitril/valsartan vs. valsartan improved mortality/morbidity in patients with left ventricular ejection fraction (LVEF) below median (57%).
Lars H. Lund, Gianluigi Savarese, Ashwin Venkateshvaran, Lina Benson, Anna Lundberg, Erwan Donal, Jean‐Claude Daubert, Emmanuel Oger, Cecilia Linde, Camilla Hage   +9 more
doaj   +1 more source

Impact of diastolic dysfunction on outcome in heart failure patients with mid‐range or reduced ejection fraction

ESC Heart Failure, 2021
Aims The role of diastolic dysfunction (DD) in prognostic evaluation in heart failure (HF) patients with impaired systolic function remains unclear.
Dan Liu, Kai Hu, Kolja Lau, Tobias Kiwitz, Katharina Robitzkat, Clara Hammel, Björn Daniel Lengenfelder, Georg Ertl, Stefan Frantz, Peter Nordbeck   +9 more
doaj   +1 more source

Genetic Risk and Atrial Fibrillation in Patients with Heart Failure [PDF]

, 2020
Aims: To study the association between an atrial fibrillation (AF) genetic risk score with prevalent AF and all-cause mortality in patients with heart failure.
Anker, Stefan D., Artola, Vicente A., Benjamin, Emelia J., Dickstein, Kenneth, Filippatos, Gerasimos S., Kloosterman, Mariëlle, Koekemoer, Andrea, Lam, Carolyn S. P., Lang, Chim, Meer, Peter van der, Metra, Marco, Nelson, Christopher P., Ng, Leong L., Ponikowski, Piotr, Rienstra, Michiel, Romaine, Simon P. R., Roselli, Carolina, Samani, Nilesh J., Santema, Bernadet T., van der Harst, Pim, Van Gelder, Isabelle C., Van Veldhuisen, Dirk Jan, Voors, Adriaan A.   +22 more
core   +3 more sources

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes

Frontiers in Cardiovascular Medicine, 2021
Traditionally, patients with heart failure (HF) are divided according to ejection fraction (EF) threshold more or <50%. In 2016, the ESC guidelines introduced a new subgroup of HF patients including those subjects with EF ranging between 40 and 49 ...
Alberto Palazzuoli, Matteo Beltrami
doaj   +1 more source

Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study. [PDF]

, 2017
BackgroundApproximately half of the patients presenting with new-onset heart failure (HF) have HF with preserved left ventricular ejection fraction (HFpEF) and HF with mid-range left ventricular ejection fraction (HFmrEF).
Amurthur, Badri, Anand, Inder S, Ardell, Jeffrey L, DiCarlo, Lorenzo A, KenKnight, Bruce H, Kumar, H Uday, Libbus, Imad, Mittal, Sanjay, Premchand, Rajendra K   +8 more
core   +1 more source

Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. [PDF]

, 2018
AIMS: We tested the hypothesis that candesartan improves outcomes in heart failure (HF) with mid-range ejection fraction [HFmrEF; ejection fraction (EF) 40-49%].
Borlaug, Chioncel, Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration, Fonarow, Koh, Lam, Lam, Lang, Lofman, Lupon, Mele, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), Nauta, Paulus, Pfeffer, Ponikowski, Rastogi, Rickenbacher, Sartipy, Solomon, Solomon, Solomon, Swedberg, Tsuji, Vedin, Yusuf   +25 more
core   +2 more sources

Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A phase 2, randomized, sham-controlled trial [PDF]

, 2018
Background -In non-randomized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), less symptoms, and greater quality of life and exercise capacity in ...
Basuray, Anupam, Burkhoff, Daniel, Fail, Peter S., Feldman, Ted, Forde-McLean, Rhondalyn, Hummel, Scott L., Kahwash, Rami, Kaye, David M., Lilly, Scott, Litwin, Sheldon, Massaro, Joseph M., Mauri, Laura, Nielsen, Christopher D., Penicka, Martin, Petrie, Mark C., Ricciardi, Mark J., Shah, Sanjiv J., van der Harst, Pim   +17 more
core   +1 more source

The Value of IGF-1 and IGFBP-1 in Patients With Heart Failure With Reduced, Mid-range, and Preserved Ejection Fraction

Frontiers in Cardiovascular Medicine, 2022
BackgroundPrevious studies have reported inconsistent results regarding the implications of deranged insulin-like growth factor 1 (IGF-1)/insulin-like growth factor-binding protein 1 (IGFBP-1) axis in patients with heart failure (HF).
Shaohua Guo, Mengqi Gong, Gary Tse, Gary Tse, Gary Tse, Guangping Li, Kang-Yin Chen, Tong Liu   +7 more
doaj   +1 more source